Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
6
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
9
Opposition chief acquitted of instigating perjury
-
10
Job creation lowest on record among under-30s
SK Bioscience receives positive results from phase 3 trial of typhoid vaccine
By Shim Woo-hyunPublished : Dec. 17, 2020 - 17:50
SK Bioscience announced Thursday that the typhoid conjugate vaccine it is developing jointly with the International Vaccine Institute has garnered positive results from phase 3 clinical trials.
The phase 3 clinical trials of vaccine material NBP618 were conducted on 1,350 people aged between 6 months and 45 years old.
The company said the test subject group has shown immune responses as effective as existing typhoid vaccines. There was no side effect found, the company added.
SK Bioscience now will take steps to debut the vaccine in the global market as early as 2022.
The firm will seek approval from the Ministry of Food and Drug Safety in South Korea as well as prequalification from the World Health Organization, which is required for the company to provide the vaccine to the global market.
The last stage in development of the typhoid conjugate vaccine was supported by a $5 million grant from the Bill & Melinda Gates Foundation.
By Shim Woo-hyun (ws@heraldcorp.com)
The phase 3 clinical trials of vaccine material NBP618 were conducted on 1,350 people aged between 6 months and 45 years old.
The company said the test subject group has shown immune responses as effective as existing typhoid vaccines. There was no side effect found, the company added.
SK Bioscience now will take steps to debut the vaccine in the global market as early as 2022.
The firm will seek approval from the Ministry of Food and Drug Safety in South Korea as well as prequalification from the World Health Organization, which is required for the company to provide the vaccine to the global market.
The last stage in development of the typhoid conjugate vaccine was supported by a $5 million grant from the Bill & Melinda Gates Foundation.
By Shim Woo-hyun (ws@heraldcorp.com)
